Internal Medicine: On Demand 1.0
|
$399.20
Use promo code (Limited Offer)
15.25 CREDITS
 |
|
A collection of recorded video lectures from conferences that took place in 2017Course Content
| Session | Title | Faculty |
| Session 1 (50 minutes) | Improving Outcomes in Heart Failure Patients with Co-morbid Metabolic Syndrome | Alanna A. Morris, MD, MSc |
| Session 2 (59 minutes) | Lipid Abnormalities in Patients with Cardio-metabolic Risk: Implications for Therapeutic Interventions | James A. Underberg, MS, MD, FACPM, FACP, FASH, FASPC, FNYAM, FNLA |
| Session 3 (60 minutes) | Minimizing CV Risk in the African-American Patient with Cardiometabolic Syndrome: Healthy Hearts 2020 | Alanna A. Morris, MD, MSc |
| Session 4 (58 minutes) | Patient-focused LDL-C Management and Risk Reduction in Clinical Practice: The Utility of PCSK9 Inhibitors | James A. Underberg, MS, MD, FACPM, FACP, FASH, FASPC, FNYAM, FNLA |
| Session 5 (51 minutes) | The Efficacy, Safety, and CV Benefits of PCSK9 Monoclonal Antibody Treatment | Peter Howard Jones, MD, FACP, FNLA |
| Session 6 (42 minutes) | Coming to Consensus in a New Era: 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies in ASCVD Risk Reduction | Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA |
| Session 7 (63 minutes) | Statins for Everyone: Examining the Potential Harms of Statins Therapy | Peter Howard Jones, MD, FACP, FNLA |
| Session 8 (42 minutes) | Understanding Risk Assessment in Primary Prevention: The Role of Baseline and Longitudinal Risk Calculators | Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA |
| Session 9 (44 minutes) | Insulin Therapy in Type 2 Diabetes | Carol H. Wysham, MD |
| Session 10 (56 minutes) | Glycemic Control and CV Risk Reduction: Time to Rethink the Approach | George Bakris, MD |
| Session 11 (51 minutes) | Management of Hyperglycemia in Type 2 Diabetes: A Case for Personalized Medicine | Carol H. Wysham, MD |
| Session 12 (44 minutes) | Treatment of Hyperglycemia in Patients with Co-Existent Diabetes and Cardiovascular Disease | Carol H. Wysham, MD |
| Session 13 (59 minutes) | Diabetic Kidney Disease: Understanding Risk, Halting Progression | George Bakris, MD |
| Session 14 (60 minutes) | Drugs, Devices and Bariatric Surgery Options: Essential Knowledge for Weight Management | Donna H. Ryan, MD |
| Session 15 (47 minutes) | Practical Strategies for Weight Management | Barbara Cerniauskas, LDN, RD, CDE |
| Session 16 (41 minutes) | White Coat Hypertension: Diagnosis, Prognosis, and Treatment | Daichi Shimbo, MD |
| Session 17 (42 minutes) | Masked Hypertension: Where are we and What Lies Ahead | Daichi Shimbo, MD |
| Session 18 (42 minutes) | Primary Aldosteronism: A Common Sense Approach | William F. Young, Jr, MD, MSc, ELS |
| Session 19 (42 minutes) | Pheochromocytma: Case-Driven Clinical Pearls | William F. Young, Jr, MD, MSc, ELS |
Program Overview
Presented by Continuing Education Company (CEC) for the past 25 years, our Primary Care CME Conference Series is designed to update primary care clinicians in rapidly changing therapeutic areas. This CME activity, Internal Medicine: On Demand Vol. 1 is comprised of recorded video lectures from conferences that took place in 2017 including the 21st Annual Hypertension, Diabetes, & Dyslipidemia Conference and the Annual Metabolic Health Conference.
The emphasis of this course is on practical and useful information for clinical practice. This activity will educate and promote improved patient outcomes in a broad range of therapeutic areas commonly encountered in internal medicine and primary care practice. This CME course will highlight the latest science related to a variety of specialty areas, presented in a practical and patient-focused manner relevant to the primary care setting.
Learning Objectives:
As a result of this activity, participants will be able to:
- Assess and provide patients with an accurate diagnosis and optimal care for a broad range of disorders seen in primary care.
- Utilize current guidelines in the diagnosis and management of commonly encountered therapeutic issues.
- Formulate comprehensive evidence-based interventions and treatment strategies that will lead to the reduction of modifiable risk factors and improved long term outcomes.
Post-Test and Evaluation:
After completing the CME activity, you must successfully complete a post-test and fill out a program evaluation form. You will then be able to view and print your CME certificate. Login into CME365™ to view your transcript and reprint your certificate at any time.
Faculty
George Bakris, MD
Professor of Medicine Director, ASH Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL
Jan N. Basile, MD, FACP, FASH
Professor of Medicine, Seinsheimer Cardiovascular Health Program, Medical University of South Carolina, Ralph H. Johnson VA Medical Center, Charleston, SC
Barbara Cerniauskas, LDN, RD, CDE
Nutrition Education and Training Manager, Office of Public Health, Baton Rouge, LA
Peter Howard Jones, MD, FACP, FNLA
Director, Weight Management Center, Houston Methodist Hospital, Associate Professor of Medicine, Center for Cardiovascular Disease Prevention, Houston Methodist DeBakey Heart and Vascular Center, Baylor College of Medicine, Houston, TX
Alanna A. Morris, MD, MSc
Assistant Professor of Medicine, Division of Cardiology, Heart Failure Therapy and Transplantation, Emory University School of Medicine, Atlanta, GA
Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Associate Professor of Medicine, Division of Cardiology, Medical University of South Carolina, Columbia, SC
Donna H. Ryan, MD
Professor Emerita, Pennington Biomedical Research Center, Baton Rouge, LA
Daichi Shimbo, MD
Associate Professor of Medicine, Ewig Clinical Scholar, Department of Medicine, Columbia University, New York City, NY
James A. Underberg, MS, MD, FACPM, FACP, FASH, FASPC, FNYAM, FNLA
Clinical Lipidologist, Clinical Assistant Professor of Medicine, NYU Center for Prevention of Cardiovascular Disease Director, Bellevue Hospital Lipid Clinic, NYU School of Medicine, New York, NY
Carol H. Wysham, MD
Clinical Professor of Medicine, University of Washington School of Medicine, Clinical Endocrinologist, Spokane, WA
William F. Young, Jr, MD, MSc, ELS
Professor of Medicine, Mayo Clinical College of Medicine, Rochester, MN
Accreditation
AMA PRA Category 1 Credits™: Continuing Education Company, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Continuing Education Company, Inc. designates this enduring material for a maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST complete the activity and the evaluation form. For ABIM MOC points, your information will be shared with the ABIM through the ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
AAPA: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 15.25 hours of Category I credit for completing this activity.
AANPCP: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Release Date: 6/14/2018
Reviewed: 2/12/2019
Re-release Date: 6/14/2019
Expiration Date: 6/14/2021 (Date after which this enduring material is no longer certified for credit.)
Medium: Enduring Material, Video/Audio
Faculty/Planning Committee Disclosures
Review and Planning Committee Disclosures:
The following individuals have indicated that he/she (nor spouse/partner) has no relevant financial relationships with a commercial interest that may impact upon this CME activity:
- Ronald Jendry, MD - Reviewer
- Walter Ejnes, CHCP - Reviewer & Planning Committee (Continuing Education Company)
- Beth Townsend - Reviewer (Continuing Education Company)
- Su Barnwell - Planning Committee (Continuing Education Company)
Faculty Disclosures:
The following individuals have indicated that he/she (nor spouse/partner) have no relevant financial relationships with a commercial interest that may impact upon this CME activity:
| Faculty | Disclosure |
| George Bakris, MD | Research Grant: Abbvie, Bayer-Research Support, Janssen *Research Grants paid to University of Chicago Medicine Consultant: CoVance, Ionis, Relypsa |
| Jan N. Basile, MD, FACP, FASH | Speaker's Bureau: Amgen, Arbor, Janssen Consultant: Medtronic, Novartis, Up-to-Date Research Grant: Eli Lilly (REWIND), NHLBI (SPRINT) |
| Barbara Cerniauskas, LDN, RD, CDE | Has no relevant financial interests or relationships to disclose. |
| Peter Howard Jones, MD, FACP, FNLA | Advisory Board: Amgen, Sanofi/Regeneron |
| Alanna A. Morris, MD, MSc | Consultant/Consulting Fees: Novartis |
| Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA | Advisory Board: Amgen, AstraZeneca, Sanofi/Regeneron |
| Donna H. Ryan, MD | Speaker's Bureau: Eisai, Novo Nordisk, Orexigen Therapeutics Consultant: AstraZeneca, CVK Pharmaceuticals, KVK Tech, Kwangdong, Scientific Intake Advisory Board: Gila Therapeutics, Janssen, Merck, Novo Nordisk, Orexigen Therapeutics, Rhythm Ownership Interest: Gila Therapeutics, Scientific Intake |
| Daichi Shimbo, MD | Consultant: Novartis |
| James A. Underberg, MS, MD, FACPM, FACP, FASH, FASPC, FNYAM, FNLA | Research Grant/Grant Receipt: Aegerion, Pfizer Advisory Board: Akcea, Alexion, Amgen, Regeneron, Sanofi Speaker's Bureau: Alexion, Amgen, Regeneron, Sanofi Honoraria: Alexion, Amgen, Sanofi Consultant: Amarin, Amgen |
| Carol H. Wysham, MD | Speaker's Bureau: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Insulet, Janssen, Novo Nordisk, Sanofi Aventis Advisory Board: AstraZeneca, BD, Boehringer-Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi Aventis Consultant: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi Aventis |
| William F. Young, Jr, MD, MSc, ELS | Consultant: Nihon Medi-Physics |
Unlabeled Use Declaration:
During their presentation, faculty may discuss unlabeled or investigational use which is not approved for a commercial product. Faculty members are required to disclose this information to the audience when referring to an unlabeled or investigational use.
Statement of Disclosure and Independence:
It is the policy of Continuing Education Company (CEC) to ensure all of its accredited educational activities are designed, implemented, and evaluated in accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Criteria and Policies. In accordance with ACCME requirements, CEC has Conflict of Interest (COI) and Disclosure Policies that are designed to ensure that accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor.
All individuals who are in position to influence and/or control content of a CEC accredited Continuing Medical Education (CME) activity must disclose any relevant financial interest or other relationships which they or their spouse/partner have with (a) with the manufacturer(s) of any commercial products(s) and/or provider(s) of commercial services discussed in an educational presentation and (b) with any commercial supporters of the activity. (Relevant financial interest or other relationship includes such things as grants or research support, employee, consultant, major stockholder, member of speakers’ bureau, etc.) The intent of this disclosure is to provide activity participants with information to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusions. All potential conflicts of interest have been identified and resolved, and are listed above.
The opinions, ideas, recommendations, and perspectives expressed in the syllabus and accompanying presentations at this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Continuing Education Company, advisory boards or consultants.
Computer Requirements
Flash Player 10 or later, and one of the following browsers:
- Windows: Internet Explorer 6 and later, Microsoft Edge (latest version), Firefox 1.x and later, Google Chrome (latest version), Opera 9.5 and later
- Mac: Safari 3 and later, Firefox 1.x and later, Google Chrome (latest version)
- Linux: Firefox 1.x and later
HTML5 via one of the following browsers:
- Windows: Google Chrome (latest version)
- Mac: Safari 6.0.5 or later, Google Chrome (latest version)
- Mobile: Safari in Apple iOS 6 or later
30 Day Money Back Guarantee
CEC stands behind our product. If you are not satisfied with your online course for any reason, send a written cancellation request and reason to registration-info@cmemeeting.org within 30 days of the purchase date for a full refund. Please note you may watch any of the content but once you claim credit for any online course, no refund can be granted.